EUCTR2018-000966-12-DE进行中（未招募）1 期
A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients with Cystic Fibrosis with at Least One G542X Allele
Eloxx Pharmaceuticals Inc0 个研究点目标入组 16 人开始时间: 2019年6月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Evidence of signed and dated informed consent/assent document(s) indicating that the subject (and/or his parent/legal guardian) has been informed of all pertinent aspects of the trial
- •2.Understands, and is willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures
- •3.Males and females age 18 years and above; in countries where permitted, males and females age 16 and above
- •4.A confirmed diagnosis of nmCF with a documented G542X or phenotypically similar nonsense mutation, homozygote, or compound heterozygote with one of the specified mutations. For heterozygotes, one mutation has to be a G542X or phenotypically similar nonsense mutation, and the second mutation should be any Class 1 or Class 2 mutation. Patients with one G542X or phenotypically similar nonsense allele and a second allele that is not in the above list may be potentially allowed but only after discussion on a case by case basis with and written approval from the Sponsor.
- •5.Documented SCC = 60 mEq
- •6.FEV1 = 40% predicted normal for age, gender and height at Screening (Knudson Equation)
- •7.Stable regimen of oral CF medications, inhaled antibiotics, dornase alfa, and hypertonic saline, and physiotherapy for the period 28 days prior to Screening
- •8.Non-smokers for at least 180 days (6 months) prior to Screening
- •9.Must be willing to abstain from strenuous exercise during the 24 hours prior study visits
- •10.Females of childbearing potential and males capable of fathering a child must meet the contraception requirements outlined in Section ?6.4
- •11.Non-lactating females
- •12.Females on hormone replacement therapy (estrogen or progesterone) or contraceptive therapy must be stabilized on a product and dose for at least 30 days prior to Screening
- •13.Glomerular filtration rate (GFR) of > 60 mL/min/1.73m2 at Screening (GFR to be calculated using the Chronic Kidney Disease Epidemiology Collaboration CKD-EPI formula
- •14.Have not received systemic medications with potential to impair renal function on a frequent basis (e.g., non steroidal anti inflammatory drugs [NSAIDs]) or with ototoxic potential (e.g., quinine or salicylates), or any injectable aminoglycosides for a period of at least 14 days prior to dosing
- •15.Negative human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), and hepatitis C virus antigen (HCV Ag) serology tests at Screening
- •16.No history of alcohol or drug abuse within the 6 months prior to Screening
- •17.Body Mass Index (BMI) of 19.0 to 30.0 kg/m2 (inclusive). Patients with a lower BMI may be entered into the study at the discretion of the investigator following consultation with the Sponsor.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or patients who are Eloxx Pharmaceuticals employees directly involved in the conduct of the study
- •2.Participation in clinical study including administration of any investigational drug or device in the last 30 days or 5 half-lives (whichever is longer) prior to investigational product dosing in the current study
- •3.Use of prohibited medications as defined in Section ?6.1 within the specified windows
- •4.History of any comorbidity which in the opinion of the investigator might confound the study or pose an additional risk in administering the study drug to the patient
- •5.History of any organ transplantation
- •6.Liver disease characterized by cirrhosis or portal hypertension. Patients with alanine aminotransferase (ALT), aspartate aminotransferase (AST), and/or a total bilirubin 3.0 times the upper limit of normal (ULN) will be excluded
- •7.History of clinically significant adrenal disease needing hormone replacement therapy
- •8.History of congestive heart failure diagnosed clinically or with documented left ventricular ejection fraction (LVEF) = 40%
- •9.Evidence or history of clinically relevant psychiatric condition
- •10.A positive urine drug screen (amphetamines, benzodiazepines, cocaine and opiates) at Screening
- •11.Screening supine 12-lead electrocardiogram (ECG) demonstrating any clinically significant findings as judged by the Investigator
- •12.Patients with any abnormalities in clinical laboratory tests at Screening, considered by the study physician as clinically relevant
- •13.Major surgery within 180 days (6 months) of Screening
- •14.Patients without documented prior aminoglycoside exposure who have a mitochondrial mutation that has been shown to increase sensitivity to aminoglycosides
- •15.Known allergy to any aminoglycoside
- •16.Patients with any acute medical situation not related to CF (e.g., gastroenteritis) unresolved within 14 days of first dose that is considered of significance by the Investigator
- •17.Patients with any abnormality at ENT screening, that indicates the presence of a vestibular toxicity associated with prior exposure to aminoglycosides.
- •18.Dizziness Handicap Inventory (DHI)-H score at screening >16.
- •19.Patients receiving CFTR modulators or potentiators as defined in Section ?6.1 within 2 months of study enrollment
- •20.Patients unable to avoid foods or drinks that contain grapefruit or Seville oranges, as these may affect the amount of ivacaftor in the body. Patients who meet this exclusion criterion and have already started the study prior to Protocol Amendment 5.0 will not be allowed to proceed to Treatment Period 5
- •21.Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Patients who meet this exclusion criterion and have already started the study prior to Protocol Amendment 5.0 will not be allowed to proceed to Treatment Period 5
研究者
相似试验
招募中
1 期
Sotatercept in Children with Pulmonary Artery Hypertension on Standard of CareMedDRA version: 21.1Level: LLTClassification code 10037403Term: Pulmonary hypertension NOSSystem Organ Class: 100000004855Pulmonary arterial hypertensionEUCTR2022-000478-25-FRMerck Sharp & Dohme LLC42
进行中（未招募）
1 期
Sotatercept in Children with Pulmonary Artery Hypertension on Standard of CareMedDRA version: 21.1Level: LLTClassification code 10037403Term: Pulmonary hypertension NOSSystem Organ Class: 100000004855Pulmonary arterial hypertensionEUCTR2022-000478-25-DEMerck Sharp & Dohme LLC42
进行中（未招募）
1 期
Sotatercept in Children with Pulmonary Artery Hypertension on Standard of CareMedDRA version: 21.1Level: LLTClassification code 10037403Term: Pulmonary hypertension NOSSystem Organ Class: 100000004855Pulmonary arterial hypertensionEUCTR2022-000478-25-NLMerck Sharp & Dohme LLC42
进行中（未招募）
1 期
Sotatercept in Children with Pulmonary Artery Hypertension on Standard of CareMedDRA version: 21.1Level: LLTClassification code 10037403Term: Pulmonary hypertension NOSSystem Organ Class: 100000004855Pulmonary arterial hypertensionEUCTR2022-000478-25-PLMerck Sharp & Dohme LLC42
招募中
1 期
Sotatercept in Children with Pulmonary Artery Hypertension on Standard of CareMedDRA version: 21.1Level: PTClassification code: 10064911Term: Pulmonary arterial hypertension Class: 100000004855Pulmonary arterial hypertensionCTIS2023-504861-22-00Merck Sharp & Dohme LLC62